Size	Price	VIP Price	US Stock	Global Stock	In Stock
{[ item.pr_size ]}		Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

CAS No. :	453562-69-1
Formula :	C₂₂H₂₃N₅O
M.W :	373.45
SMILES Code :	O=C(NC1=CC2=C(C=C1)C(C)(C)CN2)C3=C(NCC4=CC=NC=C4)N=CC=C3
Synonyms :	AMG 706
MDL No. :	MFCD10567689
InChI Key :	RAHBGWKEPAQNFF-UHFFFAOYSA-N
Pubchem ID :	11667893

GHS Pictogram:
Signal Word:	Warning
Hazard Statements:	H302
Precautionary Statements:	P280-P305+P351+P338

CHO cells	starting at 3 μM	2 hours	Evaluate the inhibitory effect of Motesanib on autophosphorylation of wild-type and mutant Kit. Results showed IC50 values of 36 nM for wild-type Kit, and 5 nM, 1 nM, and 18 nM for V560D, Δ552-559, and AYins503-504 mutants, respectively	PMC2912835
Ba/F3 cells	starting at 3 μM	24 hours	Evaluate the inhibitory effect of Motesanib on Ba/F3 cell proliferation. Results showed IC50 values of 3 nM, 0.4 nM, and 11 nM for V560D, Δ552-559, and AYins503-504 mutants, respectively	PMC2912835
Human umbilical vein endothelial cells (HUVECs)	25 nM	4 days	The combination of motesanib and fractionated radiation showed additive inhibition on HUVEC proliferation.	PMC3216115
HUVECs	10 nM	72 hours	Evaluate the effect of Motesanib on HUVECs cell proliferation, results showed Motesanib inhibited endothelial cell proliferation with IC50 of 10 nM	PMC3515409
NCI-H1650	5 μM	72 hours	Evaluate the effect of Motesanib on NCI-H1650 cell proliferation, results showed 5 μM Motesanib had no effect on NCI-H1650 cell proliferation	PMC3515409
NCI-H1299	5 μM	72 hours	Evaluate the effect of Motesanib on NCI-H1299 cell proliferation, results showed 5 μM Motesanib had no effect on NCI-H1299 cell proliferation	PMC3515409
NCI-H358	5 μM	72 hours	Evaluate the effect of Motesanib on NCI-H358 cell proliferation, results showed 5 μM Motesanib had no effect on NCI-H358 cell proliferation	PMC3515409
Calu-6	5 μM	72 hours	Evaluate the effect of Motesanib on Calu-6 cell proliferation, results showed 5 μM Motesanib had no effect on Calu-6 cell proliferation	PMC3515409
A549	5 μM	72 hours	Evaluate the effect of Motesanib on A549 cell proliferation, results showed 5 μM Motesanib had no effect on A549 cell proliferation	PMC3515409
NCI-H460/MX20 cells	3 µM	72 hours	Motesanib partially reversed ABCG2-mediated multidrug resistance	PMC4133117
LLC-MDR1-WT cells	1 µM and 3 µM	72 hours	Motesanib significantly decreased the resistance of LLC-MDR1-WT cells to paclitaxel	PMC4133117
KB-C2 cells	1 µM and 3 µM	72 hours	Motesanib significantly decreased the resistance of KB-C2 cells to paclitaxel, colchicine, and vincristine	PMC4133117

Balb/C mice	C26 mouse colon adenocarcinoma model	Oral	100 mg/kg	5 times a week for two weeks	To evaluate the antitumor and antivascular activities of Motesanib in the C26 mouse colon adenocarcinoma model. Results showed that Motesanib was unevenly distributed in C26 tumors, detected at relatively high levels in only one-third of the tumors, mainly in necrotic areas.	PMC5197073
C57B6 mice	Hair depigmentation model	Oral	75 mg/kg	Twice daily for 21 days	Evaluate the inhibitory effect of Motesanib on Kit activity. Results showed significant inhibition of hair depigmentation, and this effect was reversible	PMC2912835
CD1 nu/nu mice	Calu-6 xenograft model	Oral	75 mg/kg BID	Twice daily for 17 days	Evaluate the antitumor activity of single-agent Motesanib in Calu-6 xenograft model, results showed 75 mg/kg BID significantly inhibited tumor growth (66% inhibition)	PMC3515409
Athymic nude mice	HNSCC xenograft models	Oral gavage	75 mg/kg QD or 20 mg/kg QD	5x weekly for 4 weeks	Combination therapy with motesanib and radiation significantly enhanced antitumor efficacy, reduced tumor volume, and increased intratumoral hypoxia.	PMC3216115

{[proInfo.proName]}

CAS No.: 453562-69-1

{[proInfo.proName]}

CAS No.: 453562-69-1

Alternative Products

Product Details of Motesanib

Safety of Motesanib

Related Pathways of Motesanib

Isoform Comparison

Biological Activity

Protocol

References

Historical Records

Categories

Precautionary Statements-General

Prevention

Response

Storage

Disposal

Physical hazards

Health hazards

Environmental hazards

Inquiry

Molarity Calculator

Total Compounds Calculator

Dissolution Calculator

NCT00861419	Advanced Solid Tumors	Phase 1	Completed	-	-
NCT02084732	Thyroid Cancer	Phase 2	Unknown	June 2018	Colombia ... More >> Instituto Nacional de Cancerología Recruiting Bogotá, Cundinamarca, Colombia, 00000 Contact: Yeinnyer C. Muleth, BSc 3340106 ymuleth@cancer.gov.co Principal Investigator: Luis F Fierro, Md Sub-Investigator: Gloria Garavito, Md Sub-Investigator: Andres A Cuellar, Md Sub-Investigator: Jose A. Carreño, Md Sub-Investigator: Juan S Castillo, Md Less <<
NCT01700699	-		Unknown	October 2013	Italy ... More >> Department of Medicine and Surgery, Univeristy of Salerno Recruiting Baronissi, Salerno, Italy, 84081 Contact: Mario Vitale, MD +39 089672539 mavitale@unisa.it Principal Investigator: Mario Vitale, MD Less <<
NCT00324597	Lung Cancer L... More >>ymphoma Lymphoproliferative Disorder Unspecified Adult Solid Tumor, Protocol Specific Less <<	Phase 1	Unknown	-	United States, California ... More >> Jonsson Comprehensive Cancer Center at UCLA Los Angeles, California, United States, 90095-1781 Less <<
NCT01265927	Breast Neoplasms	Phase 1	Completed	-	United States, Indiana ... More >> Indiana University Simon Cancer Center Indianapolis, Indiana, United States, 46202 Less <<
NCT00310895	Solid Tumor Malignancies	Phase 1	Completed	-	United States, Illinois ... More >> The University of Chicago Medical Center Chicago, Illinois, United States, 60637 United States, Michigan Wayne State University, Karmanos Cancer Center Detroit, Michigan, United States, 48201 Less <<
NCT00510445	Lung Cancer	Phase 1	Completed	-	United States, Maryland ... More >> University of Maryland Greenebaum Cancer Center Baltimore, Maryland, United States, 21201 United States, Texas The University of Texas Southwestern Medical Center Dallas, Texas, United States, 75390 UT MD Anderson Cancer Center Houston, Texas, United States, 77030 United States, Wisconsin University of Wisconsin, Paul P. Carbone Comprehensive Cancer Center Madison, Wisconsin, United States, 53792 Less <<
NCT00594126	Multiple Myeloma	Phase 1	Completed	-	United States, Maryland ... More >> Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University Baltimore, Maryland, United States, 21231 United States, Massachusetts Dana Farber Cancer Institute Boston, Massachusetts, United States, 02115 United States, New York Roswell Park Cancer Institute Buffalo, New York, United States, 14263 Less <<
NCT00718601	Multiple Myeloma	Phase 1	Completed	-	United States, Michigan ... More >> Karmanos Cancer Center Detroit, Michigan, United States, 48201 United States, New York St. Vincent's Comprehensive Cancer Center New York City, New York, United States, 10011 United States, Washington Fred Hutchinson Cancer Research Center Seattle, Washington, United States, 98109 Less <<
NCT00356681	Breast Neoplasms ... More >> Breast Tumors Breast Cancer Locally Recurrent and Metastatic Breast Cancer Less <<	Phase 2	Terminated(Sponsor decision to... More >> close study) Less <<	-	-
NCT00369070	Advanced Non-squamous NSCLC	Phase 2	Terminated	-	-
NCT00427349	Gastrointestinal Carcinoid Tum... More >>or Islet Cell Tumor Neoplastic Syndrome Less <<	Phase 2	Completed	-	-
NCT00360867	Solid Tumors	PHASE2	TERMINATED	2025-07-12	-
NCT00427349	-		Completed	-	-
NCT00574951	Fallopian Tube Cancer ... More >> Ovarian Cancer Primary Peritoneal Cavity Cancer Less <<	Phase 2	Terminated(Study was stopped f... More >>or severe toxicity causing concern for patients) Less <<	-	United States, California ... More >> Providence Saint Joseph Medical Center - Burbank Burbank, California, United States, 91505 United States, Connecticut George Bray Cancer Center at the Hospital of Central Connecticut - New Britain Campus New Britain, Connecticut, United States, 06050 United States, Illinois University of Illinois Cancer Center Chicago, Illinois, United States, 60612-7243 Rush University Medical Center Chicago, Illinois, United States, 60612 Hinsdale Hematology Oncology Associates Hinsdale, Illinois, United States, 60521 United States, Indiana St. Vincent Indianapolis Hospital Indianapolis, Indiana, United States, 46260 United States, Missouri St. John's Regional Health Center Springfield, Missouri, United States, 65804 Hulston Cancer Center at Cox Medical Center South Springfield, Missouri, United States, 65807 United States, New Jersey Cancer Institute of New Jersey at Cooper - Voorhees Voorhees, New Jersey, United States, 08043 United States, North Carolina Blumenthal Cancer Center at Carolinas Medical Center Charlotte, North Carolina, United States, 28232-2861 United States, Ohio Case Comprehensive Cancer Center Cleveland, Ohio, United States, 44106-5065 Mount Carmel Health - West Hospital Columbus, Ohio, United States, 43222 Lake/University Ireland Cancer Center Mentor, Ohio, United States, 44060 United States, Oklahoma Oklahoma University Cancer Institute Oklahoma City, Oklahoma, United States, 73104 United States, Pennsylvania Rosenfeld Cancer Center at Abington Memorial Hospital Abington, Pennsylvania, United States, 19001 Fox Chase Cancer Center - Philadelphia Philadelphia, Pennsylvania, United States, 19111-2497 McGlinn Family Regional Cancer Center at Reading Hospital and Medical Center Reading, Pennsylvania, United States, 19612-6052 United States, Texas Harrington Cancer Center Amarillo, Texas, United States, 79106 United States, Virginia University of Virginia Cancer Center Charlottesville, Virginia, United States, 22908 Less <<
NCT00574951	-		Terminated(Study was stopped f... More >>or severe toxicity causing concern for patients) Less <<	-	-
NCT01386866	Advanced Solid Tumors	PHASE1	COMPLETED	2025-12-10	-
NCT01273090	Brain and Central Nervous Syst... More >>em Tumors Lymphoma Lymphoproliferative Disorder Small Intestine Cancer Unspecified Childhood Solid Tumor, Protocol Specific Less <<	Phase 1	Completed	-	-
NCT00094835	Lung Cancer N... More >>on-Small Cell Lung Cancer Less <<	Phase 1 Phase 2	Completed	-	-
NCT01256762	Locally Recurrent or Metastati... More >>c Breast Cancer Less <<	Phase 2	Completed	-	-
NCT00094835	-		Completed	-	-
NCT00460317	Non-Small Cell Lung Cancer	Phase 3	Terminated(Amgen discontinued ... More >>the development of AMG706 because 20050201 did not meet its primary objective.) Less <<	-	-
NCT01568632	Solid Tumors ... More >>Lymphoma Less <<	Phase 1	Withdrawn	-	-
NCT01137968	Non-small Cell Lung Cancer	Phase 2	Completed	-	-
NCT01731951	Primary Myelofibrosis ... More >> Secondary Myelofibrosis Myeloid Malignancies Less <<	Phase 2	Completed	-	United States, Minnesota ... More >> Rochester, Minnesota, United States Less <<
NCT01243073	Essential Thrombocythemia ... More >> Polycythemia Vera Less <<	Phase 2	Completed	-	United States, California ... More >> City of Hope Duarte, California, United States, 91010 United States, Florida MDACC - Orlando Orlando, Florida, United States, 32806 United States, Illinois University of Chicago Chicago, Illinois, United States, 60637 United States, Maryland Johns Hopkins University - Bunting Blaustein Cancer Research Building Baltimore, Maryland, United States, 21205 United States, South Carolina Saint Francis Hospital Greenville, South Carolina, United States, 29601 United States, Texas MD Anderson Cancer Center Houston, Texas, United States, 77030 Germany University Hospital of Essen - West German Cancer Center Essen, Germany Medizinische Klinik II, Abt. Hämatologie und Onkologie - Johann Wolfgang Goethe Universität Frankfurt, Germany, D-60590 SLK-Kliniken GmbH Heilbronn, Germany Hematology Oncology Center - Ludwig-Maximilians, University Munich Medical School Munich, Germany, 80331 University Hospital Regensburg - Uniklinik Regensburg Regensburg, Germany Switzerland INSELSPITAL, University Hospital Bern Bern, Switzerland, CH - 3010 Less <<
NCT02011126	Hepatoblastoma ... More >> Previously Treated Childhood Rhabdomyosarcoma Recurrent Childhood Liver Cancer Recurrent Childhood Rhabdomyosarcoma Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor Recurrent Neuroblastoma Recurrent Osteosarcoma Rhabdomyosarcoma Less <<	Phase 2	Withdrawn(IND no longer availa... More >>ble.) Less <<	-	-
NCT02629848	Carcinoma, Non-Small-Cell Lung	Phase 3	Terminated(Sponsor decision to... More >> terminate the study because the study did not meet the primary endpoint.) Less <<	-	-
NCT01242930	Multiple Myeloma	Phase 2	Completed	-	United States, Maryland ... More >> University of Maryland Medical Center - M & S Greenebaum Cancer Center Baltimore, Maryland, United States, 21201 Sidney Kimmel Cancer Center Johns Hopkins Hospital Baltimore, Maryland, United States, 21231 Less <<
NCT02598661	Myelodysplastic Syndromes	Phase 3	Recruiting	February 28, 2022	-
NCT02426086	Primary Myelofibrosis	Phase 2	Active, not recruiting	April 26, 2019	-
NCT01836549	Anaplastic Astrocytoma ... More >> Anaplastic Ependymoma Astrocytoma, Grade II Ependymoma Giant Cell Glioblastoma Glioblastoma Gliosarcoma Oligodendroglioma Brainstem Tumors Less <<	Phase 2	Terminated(Due to several intr... More >>acranial hemorrhages and recommendation by the PBTC DSMB.) Less <<	-	United States, California ... More >> Childrens Hospital Los Angeles Los Angeles, California, United States, 90027-0700 Lucile Packard Children's Hospital at Stanford University Medical Center Palo Alto, California, United States, 94304 United States, District of Columbia Children's National Medical Center Washington, District of Columbia, United States, 20010-2970 United States, Illinois Lurie Children's Hospital- Chicago Chicago, Illinois, United States, 60614 United States, Maryland NCI - Pediatric Oncology Branch Bethesda, Maryland, United States, 20892 United States, New York Memorial Sloan-Kettering Cancer Center New York, New York, United States, 10065 United States, North Carolina Duke Comprehensive Cancer Center Durham, North Carolina, United States, 27710 United States, Ohio Cincinnati Children's Hospital Medical Center Cincinnati, Ohio, United States, 45229-3039 United States, Pennsylvania Children's Hospital of Pittsburgh Pittsburgh, Pennsylvania, United States, 15213 United States, Tennessee Saint Jude Children's Research Hospital Memphis, Tennessee, United States, 38105-2794 United States, Texas Texas Children's Cancer Center and Hematology Service at Texas Children's Hospital Houston, Texas, United States, 77030-2399 Less <<
NCT01836549	-		Terminated(Due to several intr... More >>acranial hemorrhages and recommendation by the PBTC DSMB.) Less <<	-	-
NCT01916187	Neuroblastoma	Phase 1	Withdrawn(drug company withdrw... More >>w support following a re-examination of the benefit-risk assessment for the investigational use of imetelstat in this population) Less <<	-	Canada, Quebec ... More >> CHU Sainte-Justine Montreal, Quebec, Canada, H3T 1C5 Less <<
NCT01349088	Breast Cancer ... More >> Metastatic Breast Cancer Stage IV Breast Cancer Less <<	Phase 1 Phase 2	Withdrawn	September 2018	United States, Pennsylvania ... More >> Thomas Jefferson University Philadelphia, Pennsylvania, United States, 19107 Less <<
NCT00121628	Thyroid Cancer	PHASE2	COMPLETED	2025-10-10	-
NCT01235416	Histologically or Cytologicall... More >>y Documented Solid Tumors Less <<	PHASE1	COMPLETED	2025-02-10	-
NCT00254267	Advanced Gastrointestinal Stro... More >>mal Tumor Less <<	PHASE2	COMPLETED	2025-12-12	-
NCT00089960	Gastrointestinal Cancer	PHASE2	COMPLETED	2025-06-08	-

Bio Calculators
Preparing Stock Solutions		1mg	5mg	10mg
Preparing Stock Solutions	1 mM 5 mM 10 mM	2.68mL 0.54mL 0.27mL	13.39mL 2.68mL 1.34mL	26.78mL 5.36mL 2.68mL
Dissolving Methods	Animal experiment Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn: in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day; The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound. Protocol 1 Protocol 2

Precautionary Statements-General
Code	Phrase
P101	If medical advice is needed,have product container or label at hand.
P102	Keep out of reach of children.
P103	Read label before use
Prevention
Code	Phrase
P201	Obtain special instructions before use.
P202	Do not handle until all safety precautions have been read and understood.
P210	Keep away from heat/sparks/open flames/hot surfaces. - No smoking.
P211	Do not spray on an open flame or other ignition source.
P220	Keep/Store away from clothing/combustible materials.
P221	Take any precaution to avoid mixing with combustibles
P222	Do not allow contact with air.
P223	Keep away from any possible contact with water, because of violent reaction and possible flash fire.
P230	Keep wetted
P231	Handle under inert gas.
P232	Protect from moisture.
P233	Keep container tightly closed.
P234	Keep only in original container.
P235	Keep cool
P240	Ground/bond container and receiving equipment.
P241	Use explosion-proof electrical/ventilating/lighting/equipment.
P242	Use only non-sparking tools.
P243	Take precautionary measures against static discharge.
P244	Keep reduction valves free from grease and oil.
P250	Do not subject to grinding/shock/friction.
P251	Pressurized container: Do not pierce or burn, even after use.
P260	Do not breathe dust/fume/gas/mist/vapours/spray.
P261	Avoid breathing dust/fume/gas/mist/vapours/spray.
P262	Do not get in eyes, on skin, or on clothing.
P263	Avoid contact during pregnancy/while nursing.
P264	Wash hands thoroughly after handling.
P265	Wash skin thouroughly after handling.
P270	Do not eat, drink or smoke when using this product.
P271	Use only outdoors or in a well-ventilated area.
P272	Contaminated work clothing should not be allowed out of the workplace.
P273	Avoid release to the environment.
P280	Wear protective gloves/protective clothing/eye protection/face protection.
P281	Use personal protective equipment as required.
P282	Wear cold insulating gloves/face shield/eye protection.
P283	Wear fire/flame resistant/retardant clothing.
P284	Wear respiratory protection.
P285	In case of inadequate ventilation wear respiratory protection.
P231 + P232	Handle under inert gas. Protect from moisture.
P235 + P410	Keep cool. Protect from sunlight.
Response
Code	Phrase
P301	IF SWALLOWED:
P304	IF INHALED:
P305	IF IN EYES:
P306	IF ON CLOTHING:
P307	IF exposed:
P308	IF exposed or concerned:
P309	IF exposed or if you feel unwell:
P310	Immediately call a POISON CENTER or doctor/physician.
P311	Call a POISON CENTER or doctor/physician.
P312	Call a POISON CENTER or doctor/physician if you feel unwell.
P313	Get medical advice/attention.
P314	Get medical advice/attention if you feel unwell.
P315	Get immediate medical advice/attention.
P320
P302 + P352	IF ON SKIN: wash with plenty of soap and water.
P321
P322
P330	Rinse mouth.
P331	Do NOT induce vomiting.
P332	IF SKIN irritation occurs:
P333	If skin irritation or rash occurs:
P334	Immerse in cool water/wrap n wet bandages.
P335	Brush off loose particles from skin.
P336	Thaw frosted parts with lukewarm water. Do not rub affected area.
P337	If eye irritation persists:
P338	Remove contact lenses, if present and easy to do. Continue rinsing.
P340	Remove victim to fresh air and keep at rest in a position comfortable for breathing.
P341	If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing.
P342	If experiencing respiratory symptoms:
P350	Gently wash with plenty of soap and water.
P351	Rinse cautiously with water for several minutes.
P352	Wash with plenty of soap and water.
P353	Rinse skin with water/shower.
P360	Rinse immediately contaminated clothing and skin with plenty of water before removing clothes.
P361	Remove/Take off immediately all contaminated clothing.
P362	Take off contaminated clothing and wash before reuse.
P363	Wash contaminated clothing before reuse.
P370	In case of fire:
P371	In case of major fire and large quantities:
P372	Explosion risk in case of fire.
P373	DO NOT fight fire when fire reaches explosives.
P374	Fight fire with normal precautions from a reasonable distance.
P376	Stop leak if safe to do so. Oxidising gases (section 2.4) 1
P377	Leaking gas fire: Do not extinguish, unless leak can be stopped safely.
P378
P380	Evacuate area.
P381	Eliminate all ignition sources if safe to do so.
P390	Absorb spillage to prevent material damage.
P391	Collect spillage. Hazardous to the aquatic environment
P301 + P310	IF SWALLOWED: Immediately call a POISON CENTER or doctor/physician.
P301 + P312	IF SWALLOWED: call a POISON CENTER or doctor/physician IF you feel unwell.
P301 + P330 + P331	IF SWALLOWED: Rinse mouth. Do NOT induce vomiting.
P302 + P334	IF ON SKIN: Immerse in cool water/wrap in wet bandages.
P302 + P350	IF ON SKIN: Gently wash with plenty of soap and water.
P303 + P361 + P353	IF ON SKIN (or hair): Remove/Take off Immediately all contaminated clothing. Rinse SKIN with water/shower.
P304 + P312	IF INHALED: Call a POISON CENTER or doctor/physician if you feel unwell.
P304 + P340	IF INHALED: Remove victim to fresh air and Keep at rest in a position comfortable for breathing.
P304 + P341	IF INHALED: If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing.
P305 + P351 + P338	IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing.
P306 + P360	IF ON CLOTHING: Rinse Immediately contaminated CLOTHING and SKIN with plenty of water before removing clothes.
P307 + P311	IF exposed: call a POISON CENTER or doctor/physician.
P308 + P313	IF exposed or concerned: Get medical advice/attention.
P309 + P311	IF exposed or if you feel unwell: call a POISON CENTER or doctor/physician.
P332 + P313	IF SKIN irritation occurs: Get medical advice/attention.
P333 + P313	IF SKIN irritation or rash occurs: Get medical advice/attention.
P335 + P334	Brush off loose particles from skin. Immerse in cool water/wrap in wet bandages.
P337 + P313	IF eye irritation persists: Get medical advice/attention.
P342 + P311	IF experiencing respiratory symptoms: call a POISON CENTER or doctor/physician.
P370 + P376	In case of fire: Stop leak if safe to Do so.
P370 + P378	In case of fire:
P370 + P380	In case of fire: Evacuate area.
P370 + P380 + P375	In case of fire: Evacuate area. Fight fire remotely due to the risk of explosion.
P371 + P380 + P375	In case of major fire and large quantities: Evacuate area. Fight fire remotely due to the risk of explosion.
Storage
Code	Phrase
P401
P402	Store in a dry place.
P403	Store in a well-ventilated place.
P404	Store in a closed container.
P405	Store locked up.
P406	Store in corrosive resistant/ container with a resistant inner liner.
P407	Maintain air gap between stacks/pallets.
P410	Protect from sunlight.
P411
P412	Do not expose to temperatures exceeding 50 oC/ 122 oF.
P413
P420	Store away from other materials.
P422
P402 + P404	Store in a dry place. Store in a closed container.
P403 + P233	Store in a well-ventilated place. Keep container tightly closed.
P403 + P235	Store in a well-ventilated place. Keep cool.
P410 + P403	Protect from sunlight. Store in a well-ventilated place.
P410 + P412	Protect from sunlight. Do not expose to temperatures exceeding 50 oC/122oF.
P411 + P235	Keep cool.
Disposal
Code	Phrase
P501	Dispose of contents/container to ...
P502	Refer to manufacturer/supplier for information on recovery/recycling

Physical hazards
Code	Phrase
H200	Unstable explosive
H201	Explosive; mass explosion hazard
H202	Explosive; severe projection hazard
H203	Explosive; fire, blast or projection hazard
H204	Fire or projection hazard
H205	May mass explode in fire
H220	Extremely flammable gas
H221	Flammable gas
H222	Extremely flammable aerosol
H223	Flammable aerosol
H224	Extremely flammable liquid and vapour
H225	Highly flammable liquid and vapour
H226	Flammable liquid and vapour
H227	Combustible liquid
H228	Flammable solid
H229	Pressurized container: may burst if heated
H230	May react explosively even in the absence of air
H231	May react explosively even in the absence of air at elevated pressure and/or temperature
H240	Heating may cause an explosion
H241	Heating may cause a fire or explosion
H242	Heating may cause a fire
H250	Catches fire spontaneously if exposed to air
H251	Self-heating; may catch fire
H252	Self-heating in large quantities; may catch fire
H260	In contact with water releases flammable gases which may ignite spontaneously
H261	In contact with water releases flammable gas
H270	May cause or intensify fire; oxidizer
H271	May cause fire or explosion; strong oxidizer
H272	May intensify fire; oxidizer
H280	Contains gas under pressure; may explode if heated
H281	Contains refrigerated gas; may cause cryogenic burns or injury
H290	May be corrosive to metals
Health hazards
Code	Phrase
H300	Fatal if swallowed
H301	Toxic if swallowed
H302	Harmful if swallowed
H303	May be harmful if swallowed